Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly.

Détails

ID Serval
serval:BIB_186255E114C9
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly.
Périodique
The European respiratory journal
Auteur(s)
Costantini A., Grynovska M., Lucibello F., Moisés J., Pagès F., Tsao M.S., Shepherd F.A., Bouchaab H., Garassino M., Aerts JGJV, Mazières J., Mondini M., Berghmans T., Meert A.P., Cadranel J.
ISSN
1399-3003 (Electronic)
ISSN-L
0903-1936
Statut éditorial
Publié
Date de publication
02/2018
Peer-reviewed
Oui
Volume
51
Numéro
2
Pages
NA
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
In May 2017, the second European Respiratory Society research seminar of the Thoracic Oncology Assembly entitled "Immunotherapy, a new standard of care in thoracic malignancies?" was held in Paris, France. This seminar provided an opportunity to review the basis of antitumour immunity and to explain how immune checkpoint inhibitors (ICIs) work. The main therapeutic trials that have resulted in marketing authorisations for use of ICIs in lung cancer were reported. A particular focus was on the toxicity of these new molecules in relation to their immune-related adverse events. The need for biological selection, currently based on immunohistochemistry testing to identify the tumour expression of programmed death ligand (PD-L)1, was stressed, as well as the need to harmonise PD-L1 testing and techniques. Finally, sessions were dedicated to the combination of ICIs and radiotherapy and the place of ICIs in nonsmall cell lung cancer with oncogenic addictions. Finally, an important presentation was dedicated to the future of antitumour vaccination and of all ongoing trials in thoracic oncology.
Mots-clé
Antibodies, Monoclonal/therapeutic use, B7-H1 Antigen/analysis, Biomarkers, Tumor, Cancer Vaccines/immunology, Carcinoma, Non-Small-Cell Lung/immunology, Carcinoma, Non-Small-Cell Lung/therapy, Clinical Trials as Topic, Congresses as Topic, Europe, Humans, Immunohistochemistry, Immunotherapy/methods, Lung Neoplasms/therapy, Oncogenes, Paris, Patient Selection, Pulmonary Medicine/organization & administration, Pulmonary Medicine/standards, Societies, Medical, Standard of Care, Thoracic Neoplasms/immunology, Thoracic Neoplasms/therapy
Pubmed
Web of science
Création de la notice
01/03/2018 21:21
Dernière modification de la notice
20/08/2019 12:48
Données d'usage